Dr Reddy’s Is Pushing For Progress On Multiple Fronts
CEO Sets Out How The Firm Is Remaining Competitive In Generics And Biosimilars
Executive Summary
Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.
You may also be interested in...
One Year On: Russia, Ukraine And The Generics Industry
On the anniversary of Russia’s invasion of Ukraine, the generics industry reflects on its contributions to relief efforts as well as the impact that the war has had on the supply chain.
Dr Reddy’s CEO Sees Strength Through Diversity
With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.
Dr Reddy’s Is Ready For Rituximab Registrations
Dr Reddy’s is preparing for rituximab filings in the US, Europe and other regions after successfully clearing clinical trials for its DRL RI proposed biosimilar rival to Rituxan.